Based on current knowledge, EGFR or HER2 is the main driver of downstream signaling in cancers that are highly sensitive to EGFR or HER2 inhibitors, primarily via the MAPK and the phosphatidylinositol 3-kinase (PI3K)/AKT pathways [21, 22]. This evidence concerns the gene PIK3CG and cancer.